Page 4 - Dr Reddy’s Laboratories
Indian generic formulation-makers level of capex declining: Candle Partners
Candle Partners study shows that from the peak of 30% of gross block in FY16, the capex is down to 9-10% of gross block
 "Indian generic formulation-makers level of capex declining: Candle Partners")
Adani Green could replace Dr Reddy's in Sensex during December review
If added, Adani Green will be the first stock from the group in Sensex. After the inclusion of Adani Enterprises by September-end, Nifty will have two Adani group constituents
 "Adani Green could replace Dr Reddy's in Sensex during December review")
At least 8 Indian companies working to develop monkeypox vaccine: Report
Among the companies that are working with ICMR are Serum Institute of India (SII), Reliance Life Sciences, Dr Reddy's Laboratories, and Biological E
 "At least 8 Indian companies working to develop monkeypox vaccine: Report")
Indian Covid vaccine makers eye regulator nod for universal boosters
Plans afoot to seek regulator nod for universal boosters
 "Indian Covid vaccine makers eye regulator nod for universal boosters")
Strong India growth boosts DRL Q1 profit by 108% to Rs 1,188 crore
The DRL stock was down marginally (0.73 per cent) to Rs 4,254 on the BSE on Thursday
 "Strong India growth boosts DRL Q1 profit by 108% to Rs 1,188 crore")
Top headlines: Dr Reddy's Q1 PAT up 108%; Adani Capital IPO likely in 2024
Bajaj Finserv on Thursday reported a 57 per cent jump in net profit at Rs 1,309 crore in the first quarter ended June 30, on healthy earnings by its subsidiary companies.
 "Top headlines: Dr Reddy's Q1 PAT up 108%; Adani Capital IPO likely in 2024")
Dr Reddy's Q1 revenue may grow up to 10% YoY, margins may expand: Analysts
Dr Reddy's Labs Q1 results preview: Analysts said that despite pricing pressures in the US, the company is likely to have recorded steady growth in this segment due to a ramp-up of new products.
 "Dr Reddy's Q1 revenue may grow up to 10% YoY, margins may expand: Analysts")
Dr Reddy's Laboratories eyes place among top five domestic pharma players
The US would continue to remain an important geography, but the firm says it hopes to double its revenues from China and grow revenues five-fold in Brazil in the next five years
From DRL to Glenmark, pharma companies see steady revenue growth in Russia
Strong sales in Q4 during war aided by 'stocking up of inventory'
 "From DRL to Glenmark, pharma companies see steady revenue growth in Russia")
Launches, base biz expansion tonic for Dr Reddy's double-digit growth
While the company's bottom line grew 10.5% annually over the 2016-17 through 2021-22 (FY22) period, it is expected to register thrice that growth rate over next two years, observes ICICI Securities
No changes in Sensex composition, Dr Reddy's remains in benchmark index
The market was expecting Tata Motors to replace DRL in the 30-share index
 "No changes in Sensex composition, Dr Reddy's remains in benchmark index")
Dr Reddy's Labs Q4 PAT falls 76% on pricing pressure, low export benefit
Dr Reddy's Q4 results: The revenue was up 15% to Rs 5,437 crore for the quarter under review
 "Dr Reddy's Labs Q4 PAT falls 76% on pricing pressure, low export benefit")
Dr Reddy's plans new brands in Russia, says no issue with funds in country
The company's Russian revenue was at Rs 686 crore for Q4FY22, a year-on-year growth of 70%.
 "Dr Reddy's plans new brands in Russia, says no issue with funds in country")
Dr Reddy's Q4 PAT may rise 28% YoY; margins likely to fall, say analysts
The pharmaceutical giant may witness some impact due to its large exposure of the business to Russia, and CIS regions.
 "Dr Reddy's Q4 PAT may rise 28% YoY; margins likely to fall, say analysts")
Dr Reddy inks $61-mn deal to acquire Cidmus brand in India from Novartis
The acquisition of Cidmus is yet another move by drug major to widen access of healthcare professionals and patients to well-established brands
Sputnik Light may soon be only version available in India amid low demand
Meanwhile, local manufacturing partners have either halted or reduced production of Sputnik Light owing to low demand
 "Sputnik Light may soon be only version available in India amid low demand")
Valuations turning attractive for Dr Reddy's as company outperforms sector
US price erosion, India growth trends would be keenly tracked
Dr Reddy's falls 3%, hits 52-week low; stock slips 10% in one month
The stock of the pharmaceutical company, which has a significant presence in the Russian market, has fallen below its previous low of Rs 4,135.90 touched on March 19, 2021
Binnopharm to acquire 2 anti-bacterial brands from Dr Reddy's
During the transition period, Dr Reddy's will continue to supply the product to Binnopharm Group to ensure availability in the market
 "Binnopharm to acquire 2 anti-bacterial brands from Dr Reddy's")
Dr Reddy's Laboratories launches generic drug in the US market
Dr Reddy's Laboratories said it has launched vasopressin injection, which is used to control frequent urination, increased thirst, and loss of water caused by diabetes, in the American market.
